Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Upgrades Warnings On Four Of Seven Drugs Flagged In Vioxx Testimony

Executive Summary

An upgrade to Abbott's Meridia riskmanagement program means FDA has taken action to strengthen warnings on four of seven drugs flagged by FDA Office of Drug Safety Associate Director David Graham, MD, during the Senate Finance Committee's hearing on Vioxx
Advertisement

Related Content

Bextra Withdrawn At FDA’s Request; Pfizer Holds Out Hope For Return
Sanofi-Aventis To Begin Long-Term Acomplia Cardio Safety Study By Fall
Obesity Drugs May Be Covered Under Part D; CMS Invites Limits On Viagra
SMART-er Isotretinoin Risk Management Program To Be Operated By Covance
AstraZeneca Crestor Ad Defends Safety, Re-Asserts Superiority Claims
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA Talking Tough On DTC: Is Viagra Letter First Of Many?
Celebrex Long-Term Safety Monitoring Results Reassure FDA
Aventis Arava Adds Physical Function Claim, Bolded Liver Safety Warning

Topics

Advertisement
UsernamePublicRestriction

Register

PS045056

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel